INTENT TO SOLE SOURCE .pdf
PDF 108 KB Posted
- Attached to
- Notice of Intent to Sole Source - FDA_2272025
- Solicitation number
- FDA_2272025
About this file
This is a Notice of Intent to Sole Source issued by the FDA announcing plans to award a Firm Fixed Price contract to Emulate Bio, located in Boston, Massachusetts. The notice cites FAR Part 6.302-1(a)(2)(ii) to justify the sole source award based on there being only one responsible source that can satisfy the agency's requirements.
The notice indicates that capability statements from other interested parties may be submitted by March 7, 2025 at 3:00 PM EST to demonstrate their ability to meet the requirements. While an award to Emulate Bio is anticipated within 10 days of the notice date (February 27, 2025), the government reserves the right to compete the contract if other capable sources are identified. The specific requirements are referenced in an attached Statement of Work that was not included in this document. Capability statements should be submitted to Contract Specialist Hilda Aryeh at the provided FDA email address.
View the file
Other files
| File | Type | Posted |
|---|---|---|
| SOW.pdf |
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
February 27, 2025
Notice of Intent to Sole Source Emulate Bio
FDA_2272025
The Food and Drug Administration (FDA) intends to award a Sole Source Firm Fixed Price contract order to Emulate Bio at 27 Dry Dock Avenue Boston, Massachusetts 02210 In accordance with FAR Part 6.302-1 (a) (2)(ii) which states” Only one responsible source and no other supplies or services will satisfy agency requirement”.
The purpose of this notice is to inform the public that the Food and Drug Administration (FDA) anticipates issuing a Firm Fixed Price contract.
MINIMUM REQUIREMENTS:
See Attached Statement of Work
This notice is not a request for competitive proposals. However, any party that believes it can meet this requirement as stated herein may submit a written capability statement that clearly supports and demonstrates their ability to perform the requirement.
Capability statements must be received by the response date and time of this notice. Submissions will be reviewed to determine if they can meet the requirement. A determination by the Government to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government.
It is anticipated that an award will be issued to Emulate Bio within approximately ten (10) days after the date of this notice unless the Government determines that any other organization has the capability to meet this requirement.
Response Date: March 7, 2025, by 3.00PM EST. Please email responses to Hilda Aryeh – hilda.aryeh@fda.hhs.gov.
Hilda Aryeh Contract Specialist mailto:hilda.aryeh@fda.hhs.gov.
File details come from the government source that posted it. Updated .